CareDx Announces Third Quarter 2026 Financial Results
Business Wire•29/10/2026•16:01 ET
0
Key Highlights
- ➤Revenue $139 million, up 39% year-over-year
- ➤GAAP net income $19 million, versus $2 million in Q3 2025
- ➤2026 revenue guidance raised to $520 million-$530 million
- ➤2026 adjusted EBITDA guidance raised to $90 million-$100 million
- ➤Naveris acquisition closed for $160 million cash plus up to $100 million contingent consideration
Expert Statements
John Hanna, President and Chief Executive Officer of CareDx
“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy. We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”
Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.